Efficacy of Aspirin in Preventing Venous Thromboembolism

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

Status and phase: Completed; Phase 4

Conditions: Venous Thromboembolism (VTE); Total Joint Arthroplasty; Total Hip Arthroplasty (THA)

Treatments: Drug: enoxaparin; Drug: Aspirin

Study type: Interventional

Funder types: Other

Identifiers

NCT06635317

151.2022 (Other Identifier)

Details and patient eligibility

About

Efficacy of aspirin and enoxaparin in preventing venous tromboembolism was compared after total knee or hip arthroplasty.

Full description

Background: Venous thromboembolism (VTE) remains a significant risk following joint replacements, despite advancements in prevention strategies. Aspirin-based therapies have gained popularity due to their perceived safety, ease of administration, and supportive evidence.This study aimed to compare the efficacy of aspirin and enoxaparin in preventing VTE after total knee or hip arthroplasty.

Methods: Sixty patients undergoing primary total knee or hip arthroplasty were randomized to receive either aspirin or enoxaparin. The primary outcome was symptomatic VTE within 90 days. Patients were followed up for Doppler ultrasound evaluations.

Enrollment: 60 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients provided written informed consent.
• All patients who underwent primary total hip or total knee arthroplasty for osteoarthritis

Exclusion criteria

• preoperative anticoagulation (direct oral anticoagulant, warfarin, IMPROVE Bleeding Score more or equal to 7, dual antiplatelet therapy)
• medical contraindications (allergy, cancer, cardiac disease, kidney disease, or bleeding disorder precluding anticoagulation).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Single Blind

---

60 participants in 2 patient groups

Long term aspirin group

Active Comparator group

Description:

Long term aspirin group received enoxaparin, 40 mg/day subcutaneously for 3 days, and aspirin, 100 mg/day orally for 25 days

Treatment:

Drug: Aspirin

Enoxaparin group

Active Comparator group

Description:

enoxaparin group received enoxaparin, 40 mg/day subcutaneously for 28 days, with the dose reduced to 20 mg for patients weighing less than 50 kg or with an estimated glomerular filtration rate less than 30 mL/min/1.73 m².

Treatment:

Drug: enoxaparin